Effect of Dolutegravir coMpared to Darunavir/Cobicistat, both with Tenofovir Disoproxil Fumarate/Emtricitabine, On the severity of neuRopsychiatric efFects at 24 weeks of treatment in people living with HIV and baseline nEuropsychiatric disorders with no prior antiretrOviral therapy experience (MORFEO)
In a phase IV trial involving treatment-experienced men with baseline neuropsychiatric vulnerabilities, the DRV/c-based regimen demonstrated superior longitudinal stabilization of depressive symptoms, sleep, and daytime functioning with fewer treatment discontinuations compared to the DTG-based regimen, despite both achieving comparable virological suppression at 24 weeks.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Living with HIV today is a very different experience than it was decades ago. Thanks to modern medicine, the virus can be suppressed so effectively that people with the infection can live long, healthy lives, often without ever passing the virus to others. The standard treatment involves a daily combination of drugs that stops the virus from multiplying. For many years, doctors have relied on a specific class of these drugs, known as integrase inhibitors, because they work quickly and are generally well-tolerated. However, a growing number of patients and doctors have noticed a troubling side effect: these powerful medications sometimes cause significant mental and emotional distress. Patients report severe insomnia, anxiety, and a deepening of existing depression. This creates a difficult dilemma for clinicians: they must choose a drug that kills the virus effectively, but they also need to ensure the patient can tolerate the treatment without their mental health deteriorating. This balance is especially critical for the many people who already struggle with mental health challenges before they even begin their HIV treatment.
A team of researchers in Mexico set out to investigate this precise problem. They conducted a clinical trial called MORFEO to compare two different treatment strategies for people who had never taken HIV medication before and who already showed signs of mental health vulnerabilities, such as trouble sleeping or feelings of depression. One group of patients received the standard integrase inhibitor, dolutegravir, combined with two other common drugs. The other group received a different type of medication, a boosted protease inhibitor called darunavir, also combined with the same two supporting drugs. The goal was not just to see which drug stopped the virus faster, but to track how each regimen affected the patients' mood, sleep, and ability to function over a six-month period. The researchers wanted to know if the drug that is usually the first choice for everyone might be too harsh for those already carrying a heavy emotional burden.
The study involved fifty-three adult men living with HIV who had documented struggles with sleep, anxiety, or depression before starting their treatment. The participants were randomly assigned to receive either the dolutegravir-based regimen or the darunavir-based regimen. Both groups took their medication daily for twenty-four weeks. Throughout this time, the researchers closely monitored the patients using standard questionnaires designed to measure the severity of insomnia, the depth of depressive feelings, and the level of anxiety. They also tracked whether the patients successfully cleared the virus from their blood and whether they were able to stay on their medication without stopping due to side effects.
The results revealed a clear and important distinction between the two treatments. Both drug combinations were highly effective at suppressing the virus; by the end of the study, the vast majority of patients in both groups had achieved undetectable levels of the virus in their blood. In terms of pure viral control, the two approaches were equally successful. However, the journey to that success looked very different for the patients depending on which drug they took. The group receiving the darunavir-based treatment showed a steady and consistent improvement across all mental health measures. Their depression scores dropped significantly, their sleep duration increased, and they reported feeling more functional during the day. In contrast, the group taking the dolutegravir-based treatment did not see the same level of improvement in their depressive symptoms or their ability to sleep through the night. While their anxiety levels did improve, their struggles with low mood and daytime fatigue persisted.
Perhaps the most telling finding was related to how many patients were able to stay on their medication. The study found that patients assigned to the dolutegravir group were more than twice as likely to stop their treatment early compared to those on the darunavir group. The researchers identified that patients who started the study with severe insomnia were at an especially high risk of dropping out, regardless of which drug they took, but the risk was compounded if they were taking dolutegravir. The data suggests that for patients who already suffer from significant mental health issues, the integrase inhibitor, despite its popularity, may trigger or worsen symptoms that make it impossible for them to continue their care. The protease inhibitor, while causing more stomach upset in the early weeks, appeared to offer a more stable environment for the mind, allowing patients to stick with their treatment and maintain their mental well-being.
This study does not suggest that the standard integrase inhibitor is a bad drug for everyone. It works exceptionally well for the general population. However, it highlights a critical gap in how HIV treatment is currently selected. The findings indicate that for the specific subgroup of patients who enter treatment with pre-existing mental health vulnerabilities, a different path may be safer. The researchers conclude that before prescribing the first dose of HIV medication, doctors should carefully screen for signs of depression and insomnia. For those who show these signs, choosing a protease inhibitor like darunavir might be the wiser choice, ensuring that the treatment cures the virus without breaking the patient's spirit. The ultimate goal of HIV care is not just to clear the virus from the blood, but to support the whole person, and sometimes that means choosing a medication that is gentler on the mind, even if it is slightly more complex to take.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.